About the Company
Cantabio Pharmaceuticals Inc. is a preclinical stage biotechnology company focusing on commercializing novel therapies and the intellectual property generated from our research and development activities for Parkinson’s disease (PD), Alzheimer’s disease (AD) and other related neurodegenerative diseases. Our strategy integrates a detailed therapeutic focus, target family biophysics, and drug discovery technology and expertise into an innovative drug discovery approach, which is currently identifying and developing small molecule pharmacological chaperones for clinical trials. In addition, the company is developing therapeutic proteins that can pass through the blood-brain barrier to supplement existing levels of proteins which display loss of function during disease conditions.
Cantabio Pharmaceuticals to Present at 2017 Silicon Valley Bank Healthcare Capital and Connections Summit in Shanghai
SAN FRANCISCO, CA–(Marketwired – September 13, 2017) – Cantabio Pharmaceuticals, Inc. (CTBO), a biopharmaceutical company developing novel disease modifying therapies for Alzheimer’s, Parkinson’s and other related neurodegenerative diseases, today announced that its CEO, Dr Gergely Tóth, will present at the 2017...
Cantabio announces publication of study on a mechanism by which the DJ-1 protein loses its defensive function in neurodegenerative disease conditions
SUNNYVALE, CA–(Marketwired – September 11, 2017) – Cantabio Pharmaceuticals, Inc. (CTBO) (“Cantabio” or the “Company”), a preclinical stage pharmaceutical company developing disease modifying therapeutics for Alzheimer’s Disease (AD), Parkinson’s Disease (PD) and related neurodegenerative diseases today announced a publication lead authored by...